Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Purpose To develop a model of X-linked inhibitor of apoptosis (XIAP) down regulation in colorectal cancer cell lines. This may be used to determine whether combination strategies have clinical potential.Methods A series of clones were developed using short hairpin RNA (shRNA) against XIAP stably expressed in HCT116 cells. XIAP mRNA and protein levels were established by RT-PCR and Immunoblot, respectively. GeneChip microarrays confirmed XIAP knockdown and absence of compensation by other IAP members.Results Four XIAP knockdown cell lines show 82-93% reduction in XIAP mRNA and 67-89% reduction in protein when compared to four luciferase control cell lines. XIAP knockdown sensitises cells to rhTRAIL by a factor of 3, to paclitaxel and docetaxel by a factor of >2 and, to a lesser extent, radiotherapy (20% enhancement).Conclusions Clinical trials with XIAP antisense continue, and these data suggest combination studies with agents such as rhTRAIL and taxanes should be undertaken.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have shown that XIAP can promote resistance of CRC cells to apoptosis induced by multiple tumor treatments [251,252,253].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [251]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“Subsequent P values were subjected to multiple testing correction using Benjamini and Hochberg’s method for controlling the false discovery rate [ 25 ].”
MethodBioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172 · cited 1×
“Data were analysed using Bioconductor 1.8 [ 19 ] running on R 2.3.0 [20].”
MethodInfluentialSmyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766 · cited 2×
“Paclitaxel and docetaxel were added over a concentration range to exponentially growing cells and incubated for 72 h prior to SRB assay [ 26 ].”
Methodlimma: Linear Models for Microarray Data
Smyth, G. K. (2005) · Statistics for Biology and Health · doi:10.1007/0-387-29362-0_23 · Cited by 5,796
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218 · cited 1×
“Expression measures were calculated using the ‘AVy’ package’s Robust Multichip Average (RMA) default method [ 21 ].”
MethodSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., & Takahashi, R. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00341-0 · Cited by 1,116 · cited 1×
“Other factors which have been reported as showing interactions with XIAP on literature review (MURR1 [28], akt2 [29], smac/Diablo [30], XAF1 [31], htra2/omi [ 32 ], apaf1 [12], GSPT1 [33] and NFKB [34]) were unchanged (Fig. 2a, b). The above results con-Wrm speciWc and stable 80% down regulation of XIAP with no impact…”
BackgroundMechanism of XIAP-Mediated Inhibition of Caspase-9
Shiozaki, E. N., Chai, J., Rigotti, D. J., Riedl, S. J., Li, P., Srinivasula, S. M., Alnemri, E. S., Fairman, R., & Shi, Y. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00054-6 · Cited by 719 · cited 1×
“The main function of XIAP is inhibition of executioner caspases 3 and 7 [3] and initiator caspase 9 [ 4 ], and XIAP is the only member of the family to inhibit both phases of the cascade directly [5].”
BackgroundExpression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A. P., et al. (2000) · PubMed · Cited by 703
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X., & Harran, P. G. (2004) · Science · doi:10.1126/science.1098231 · Cited by 656 · cited 1×
“Other factors which have been reported as showing interactions with XIAP on literature review (MURR1 [28], akt2 [29], smac/Diablo [ 30 ], XAF1 [31], htra2/omi [32], apaf1 [12], GSPT1 [33] and NFKB [34]) were unchanged (Fig. 2a, b). The above results con-Wrm speciWc and stable 80% down regulation of XIAP with no impact…”
Background(1998) · British Journal of Cancer · doi:10.1038/bjc.1998.1 · Cited by 654
Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J. A., Binder, B. R., & Lipp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.1.211 · Cited by 635 · cited 1×
“Other factors which have been reported as showing interactions with XIAP on literature review (MURR1 [28], akt2 [29], smac/Diablo [30], XAF1 [31], htra2/omi [32], apaf1 [12], GSPT1 [33] and NFKB [ 34 ]) were unchanged (Fig. 2a, b). The above results con-Wrm speciWc and stable 80% down regulation of XIAP with no impact…”
BackgroundTrends in cancer incidence and mortality in Scotland: description and possible explanations
Swerdlow, A., dos Santos Silva, I., Reid, A., Qiao, Z., Brewster, D., & Arrundale, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.424 · Cited by 532
AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer
Motoshima, H., Goldstein, B. J., Igata, M., & Araki, E. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108324 · Cited by 527 · cited 1×
“AMPK, the catalytic subunit of which was found to be up regulated in these XIAP knockdown clones, is thought to function as a suppressor of cell proliferation; [ 39 ] hence, providing a potential explanation for the growth delay in these cells although further studies would be required.”
BackgroundInhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice
Schimmer, A. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1918 · Cited by 512 · cited 1×
“This is to be expected, as it is now known that role of IAPs extend beyond caspase inhibition; there is evidence for eVects on cell division, cell cycle progression and signal transduction [9, 38 ].”
BackgroundApoptosis pathways in cancer and cancer therapy
Debatin, K.-M. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0474-8 · Cited by 476 · cited 1×
“Failure of cancer cell death and resistance to therapeutic treatments is partly due to failure to activate these pathways [ 1 ].”
BackgroundIdentification of XAF1 as an antagonist of XIAP anti-Caspase activity
Liston, P., Fong, W. G., Kelly, N. L., Toji, S., Miyazaki, T., Conte, D., Tamai, K., Craig, C. G., McBurney, M. W., & Korneluk, R. G. (2001) · Nature Cell Biology · doi:10.1038/35055027 · Cited by 441
Characterization of XIAP-Deficient Mice
Harlin, H., Reffey, S. B., Duckett, C. S., Lindsten, T., & Thompson, C. B. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3604-3608.2001 · Cited by 422 · cited 2×
“In the XIAP knockout mouse [ 35 ], there were increases in cIAP1 and cIAP2 protein levels and this may be the case in a model with complete XIAP loss rather than 80% down regulation.”
BackgroundXIAP inhibits caspase‐3 and ‐7 using two binding sites: evolutionarily conserved mechanism of IAPs
Scott, F. L., Denault, J., Riedl, S. J., Shin, H., Renatus, M., & Salvesen, G. S. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600544 · Cited by 421 · cited 1×
“The main function of XIAP is inhibition of executioner caspases 3 and 7 [ 3 ] and initiator caspase 9 [4], and XIAP is the only member of the family to inhibit both phases of the cascade directly [5].”
BackgroundAn IAP-IAP Complex Inhibits Apoptosis
Dohi, T., Okada, K., Xia, F., Wilford, C. E., Samuel, T., Welsh, K., Marusawa, H., Zou, H., Armstrong, R., Matsuzawa, S.-I., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400236200 · Cited by 398 · cited 1×
“Survivin has a role in cell division and is thought to stabilise XIAP by formation of an IAP-IAP complex [ 7 ].”
BackgroundThe Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases
Eckelman, B. P., & Salvesen, G. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510863200 · Cited by 391 · cited 1×
“It is debatable whether other members of the IAP group inhibit caspases, cIAP1 and cIAP2 have recently been shown to bind to but not inhibit caspases [ 6 ], questioning their role in the apoptotic pathway.”
BackgroundYang, L. P. H., Cao, Z., Yan, H. M., & Wood, W. C. (2003) · PubMed · Cited by 322
UKCCCR guidelines for the welfare of animals in experimental neoplasia
(1988) · Laboratory Animals · doi:10.1258/002367788780746467 · Cited by 308
Targeting XIAP for the treatment of malignancy
Schimmer, A. D., Dalili, S., Batey, R. A., & Riedl, S. J. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401826 · Cited by 304
Elevated expression of inhibitor of apoptosis proteins in prostate cancer.
Krajewska, M., Krajewski, S., Banares, S., Huang, X., Turner, B., Bubendorf, L., Kallioniemi, O., Shabaik, A. S., Vitiello, A., Peehl, D. M., et al. (2003) · PubMed · Cited by 285
Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0950 · Cited by 247 · cited 2×
“TRAIL receptor antibodies have been shown to delay colorectal xenograft tumour growth [40] and are in early clinical development [47, 48 ].The shXIAP cells developed here are threefold more sensitive to TRAIL in vitro compared to vector control cells.”
BackgroundA novel role for XIAP in copper homeostasis through regulation of MURR1
Burstein, E., Ganesh, L., Dick, R. D., van De Sluis, B., Wilkinson, J. C., Klomp, L. W., Wijmenga, C., Brewer, G. J., Nabel, G. J., & Duckett, C. S. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600031 · Cited by 222 · cited 2×
“Other factors which have been reported as showing interactions with XIAP on literature review (MURR1 [ 28 ], akt2 [29], smac/Diablo [30], XAF1 [31], htra2/omi [32], apaf1 [12], GSPT1 [33] and NFKB [34]) were unchanged (Fig. 2a, b). The above results con-Wrm speciWc and stable 80% down regulation of XIAP with no impact…”
BackgroundCummins, J. M., Kohli, M., Rago, C., Kinzler, K. W., Vogelstein, B., & Bunz, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0046 · Cited by 200 · cited 5×
“In colorectal cancer, there is evidence for XIAP as a therapeutic target in vitro in combination with TRAIL [ 36 , 44], in a mouse model of hepatic metastasis in vivo [45] and in clinical samples [29, 46].”
BackgroundMethodResultInfluentialTaxol Induces Caspase-10-dependent Apoptosis
Park, S.-J., Wu, C.-H., Gordon, J. D., Zhong, X., Emami, A., & Safa, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406543200 · Cited by 198 · cited 1×
“Paclitaxel has been shown to induce caspase 10 dependent apoptosis [ 50 ], which is a component of the extrinsic pathway (involving the TRAIL receptors DR4 and DR5).”
BackgroundMcManus, D. C., Lefebvre, C. A., Cherton-Horvat, G., St-Jean, M., Kandimalla, E. R., Agrawal, S., Morris, S. J., Durkin, J. P., & LaCasse, E. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207967 · Cited by 170
Cao, C., Mu, Y., Hallahan, D. E., & Lu, B. (2004) · Oncogene · doi:10.1038/sj.onc.1207929 · Cited by 161 · cited 3×
“Another approach using antisense oligonucleotides showed an increased sensitivity to ionising radiation in NSCLC cells [ 42 ] and to TRAIL in renal cancer cells [13].”
BackgroundInfluentialBuchsbaum, D. J., Zhou, T., Grizzle, W. E., Oliver, P. G., Hammond, C., Zhang, S., Carpenter, M., & LoBuglio, A. F. (2003) · PubMed · Cited by 154
Ferreira, C. G., van der Valk, P., Span, S. W., Ludwig, I., Smit, E. F., Kruyt, F. A. E., Pinedo, H. M., van Tinteren, H., & Giaccone, G. (2001) · PubMed · Cited by 141
LaCasse, E. C., Cherton-Horvat, G. G., Hewitt, K. E., Jerome, L. J., Morris, S. J., Kandimalla, E. R., Yu, D., Wang, H., Wang, W., Zhang, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0608 · Cited by 128 · cited 1×
“There is evidence that XIAP knockdown sensitises to taxane therapy in prostate and lung cancer models [ 49 ] and the data presented here would concur.”
BackgroundOverexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis
Mizutani, Y., Nakanishi, H., Li, Y., Matsubara, H., Yamamoto, K., Sato, N., Shiraishi, T., Nakamura, T., Mikami, K., Okihara, K., et al. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.919 · Cited by 127
Marini, P., Denzinger, S., Schiller, D., Kauder, S., Welz, S., Humphreys, R. C., Daniel, P. T., Jendrossek, V., Budach, W., & Belka, C. (2006) · Oncogene · doi:10.1038/sj.onc.1209516 · Cited by 123
Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function
Wright, C. W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26251 · Cited by 114 · cited 2×
“The main function of XIAP is inhibition of executioner caspases 3 and 7 [3] and initiator caspase 9 [4], and XIAP is the only member of the family to inhibit both phases of the cascade directly [ 5 ].”
BackgroundRegulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells
Vogler, M., Dürr, K., Jovanovic, M., Debatin, K., & Fulda, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209776 · Cited by 109
Hegde, R., Srinivasula, S. M., Datta, P., Madesh, M., Wassell, R., Zhang, Z., Cheong, N., Nejmeh, J., Fernandes-Alnemri, T., Hoshino, S.-I., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303179200 · Cited by 96 · cited 1×
“Other factors which have been reported as showing interactions with XIAP on literature review (MURR1 [28], akt2 [29], smac/Diablo [30], XAF1 [31], htra2/omi [32], apaf1 [12], GSPT1 [ 33 ] and NFKB [34]) were unchanged (Fig. 2a, b). The above results con-Wrm speciWc and stable 80% down regulation of XIAP with no impact…”
BackgroundKrajewska, M., Kim, H., Kim, C., Kang, H., Welsh, K., Matsuzawa, S.-I., Tsukamoto, M., Thomas, R. G., Assa-Munt, N., Piao, Z., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0094 · Cited by 92 · cited 2×
“XIAP mRNA is elevated in human prostate and lung tumours [10, 11], and in clinical colorectal tumour samples increases in XIAP protein levels have been found when compared to normal tissue [ 12 ].”
BackgroundRavi, R. K., Jain, A. J., Schulick, R. D., Pham, V., Prouser, T. S., Allen, H. E., Mayer, E.-G., Yu, H., Pardoll, D. M., Ashkenazi, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2488 · Cited by 83 · cited 1×
“In colorectal cancer, there is evidence for XIAP as a therapeutic target in vitro in combination with TRAIL [36, 44], in a mouse model of hepatic metastasis in vivo [ 45 ] and in clinical samples [29, 46].”
BackgroundLiu, S. S., Tsang, B. K., Cheung, A., Xue, W. C., Cheng, D. K.-L., Ng, T. Y., Wong, L. C., & Ngan, H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00085-5 · Cited by 77 · cited 1×
“However, in cervical cancers, XIAP did not show any prognostic signiWcance [ 14 ], and in radically resected NSCLC, high levels of XIAP were associated with increased survival and were inversely correlated with proliferation markers [15].”
BackgroundExpression of IAP family proteins in colon cancers from patients with different age groups
Endo, T., Abe, S., Seidlar, H., Nagaoka, S., Takemura, T., Utsuyama, M., Kitagawa, M., & Hirokawa, K. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0534-8 · Cited by 70 · cited 1×
“In colorectal cancer, there is evidence for XIAP as a therapeutic target in vitro in combination with TRAIL [36, 44], in a mouse model of hepatic metastasis in vivo [45] and in clinical samples [29, 46 ].”
BackgroundSchwab, M., Reynders, V., Loitsch, S., Shastri, Y. M., Steinhilber, D., Schroder, O., & Stein, J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn118 · Cited by 70 · cited 2×
“Schwab et al. [ 9 ] describe a decrease in XIAP when colorectal cancer cell lines were incubated with mesalazine suggesting a role for this drug in the chemoprevention of colorectal cancer in patients with inXammatory bowel disease.”
BackgroundXIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland
Olayioye, M. A., Kaufmann, H., Pakusch, M., Vaux, D. L., Lindeman, G. J., & Visvader, J. E. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401524 · Cited by 63
Takeuchi, H., Kim, J., Fujimoto, A., Umetani, N., Mori, T., Bilchik, A. J., Turner, R., Tran, A. N., Kuo, C. T., & Hoon, D. S. �. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0479 · Cited by 60 · cited 2×
“In colorectal cancer, there is evidence for XIAP as a therapeutic target in vitro in combination with TRAIL [36, 44], in a mouse model of hepatic metastasis in vivo [45] and in clinical samples [ 29 , 46].”
BackgroundDetachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells
Liu, Z., Li, H., Wu, X., Yoo, B. H., Yan, S. R., Stadnyk, A. W., Sasazuki, T., Shirasawa, S., LaCasse, E. C., Korneluk, R. G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209753 · Cited by 60
Research works printed but not linked: 1
- Ranson M, Ward T, Cummings J et al (2005) A Phase 1 Trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors. Clin Cancer Res 11(24, Part 2):8965s–9216s
Cited by
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
“Experimental manipulation of FLIP (Wilson et al, 2007) and XIAP (Toscano et al, 2008; Connolly et al, 2009; Wilson et al, 2009) has confirmed their critical role in mediating resistance against TRAIL-R-dependent apoptosis.”
BackgroundDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Inhibitors of apoptosis: clinical implications in cancer
Mohamed, M. S., Bishr, M. K., Almutairi, F. M., & Ali, A. G. (2017) · Apoptosis · doi:10.1007/s10495-017-1429-4 · Cited by 159
“Using the antisense approach, inhibition of XIAP has been reported to improve tumor control by radiotherapy and chemotherapy [216].”
BackgroundLing, X., Cao, S., Cheng, Q., Keefe, J. T., Rustum, Y. M., & Li, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045571 · Cited by 141
Svoboda, M., Šáňa, J., Fabián, P., Kocáková, I., Gombošová, J., Nekvindová, J., Radová, L., Vyzula, R., & Slabý, O. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-195 · Cited by 136
“It was shown that knockdown of XIAP in vitro lead to sensitization of colon cancer cells to irradiation [30].”
Background
Metadata
- Authors
- Connolly, K., Mitter, R., Muir, M., Jodrell, D., & Guichard, S.
- Affiliations
- Edinburgh Cancer Research (GB)
- Cancer Research UK (GB)
- University of Cambridge (GB)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Connolly, Kate
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2008-11-26
- Volume
- 64
- Issue
- 2
- Pages
- 307-316
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2001633094
- Cited by
- 34
- References
- 49
- Citations by year
- 2023: 1 · 2022: 2 · 2021: 3 · 2020: 1 · 2019: 2 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 5 · 2012: 5
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (C96/A4743)
- University of Manchester
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- XIAP, X-linked inhibitor of apoptosis, HCT116 cells, colorectal cancer, shRNA, gene knockdown, TRAIL, paclitaxel, docetaxel, radiosensitization, apoptosis inhibitor, combination therapy
- MeSH terms
- Animals, Colonic Neoplasms, Flow Cytometry, Gamma Rays, Humans, Mice, Nude, RNA, Messenger, Tumor Cells, Cultured, Immunoblotting, Reverse Transcriptase Polymerase Chain Reaction, Caspases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Xenograft Model Antitumor Assays, RNA, Small Interfering, Taxoids, Cell Proliferation, Mice, X-Linked Inhibitor of Apoptosis Protein, TNF-Related Apoptosis-Inducing Ligand, Gene Knockdown Techniques, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.